journal article·2019-10-23

Targeting the Cell Membrane by Charge-Reversal Amphiphilic Pillar[5]arene for the Selective Killing of Cancer Cells

Yincheng Chang, Jian-Yu Chen, Jinpeng Yang, Tao Lin, Lingda Zeng, Jiang-Fei Xu, Jun-Li Hou, Xi Zhang

ACS Applied Materials & Interfaces· Volume 11· Issue 42
Publisher page

Abstract

A charge-reversal amphiphilic pillar[5]arene, P5NH-DCA, bearing 10 charge-reversal headgroups is reported. It targets the cell membrane of cancer cells and selectively destroys the cancer cells by disrupting the membrane. In the acidic tumor microenvironment, the headgroup charge of P5NH-DCA reversed from negative to positive owing to hydrolysis of the acid-labile amide group. The hydrolyzed product bearing multiple positive charges can bind to the cell membrane and then disrupt the membrane of cancer cells with high efficiency. However, under the neutral microenvironment of healthy cells, the negatively charged P5NH-DCA remains stable and the cytotoxicity is considerably reduced. The strategy killing the cancer cells by membrane disruption may represent a new route of cancer chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Supramolecular Chemistry and Complexes · Nanoplatforms for cancer theranostics · Molecular Sensors and Ion Detection

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Lab of Organic Optoelectronics & Molecular Engineering, Department of Chemistry, Tsinghua University, Beijing 100084, China

Department of Chemistry, Fudan University, Shanghai 200438, China

Funding

Ministry of Science and Technology of the People's Republic of China · China Postdoctoral Science Foundation

References (29)

Show source-provided references
1. 10.1007/s11426-018-9397-510.1007/s11426-018-9397-5 ↗
2. 10.1021/acsami.7b1792710.1021/acsami.7b17927 ↗
3. 10.31635/ccschem.019.2018001110.31635/ccschem.019.20180011 ↗
4. 10.1021/acsami.7b1932510.1021/acsami.7b19325 ↗
5. 10.31635/ccschem.019.2018001510.31635/ccschem.019.20180015 ↗
6. 10.1002/adma.20160662810.1002/adma.201606628 ↗
7. 10.1002/anie.20190088410.1002/anie.201900884 ↗
8. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
9. 10.1002/adma.20160552910.1002/adma.201605529 ↗
10. 10.1021/acsnano.8b0328510.1021/acsnano.8b03285 ↗
11. 10.1021/acs.accounts.8b0049310.1021/acs.accounts.8b00493 ↗
12. 10.1002/adfm.20170308310.1002/adfm.201703083 ↗
13. 10.1002/smll.20170316410.1002/smll.201703164 ↗
14. 10.1021/ja505212y10.1021/ja505212y ↗
15. 10.1002/polc.507051011110.1002/polc.5070510111 ↗
16. 10.1021/acs.jmedchem.5b0137510.1021/acs.jmedchem.5b01375 ↗
17. 10.1021/ja210569f10.1021/ja210569f ↗
18. 10.1021/am400220s10.1021/am400220s ↗
19. 10.1021/acsami.8b0666010.1021/acsami.8b06660 ↗
20. 10.1021/ja711260m10.1021/ja711260m ↗
21. 10.1021/ja302998q10.1021/ja302998q ↗
22. 10.1021/jacs.7b1315610.1021/jacs.7b13156 ↗
23. 10.1021/ja405014r10.1021/ja405014r ↗
24. 10.1039/c8fd00009c10.1039/c8fd00009c ↗
25. 10.1021/jacs.5b0689210.1021/jacs.5b06892 ↗
26. 10.1002/anie.20080096310.1002/anie.200800963 ↗
27. 10.1021/ja00517a03310.1021/ja00517a033 ↗
28. Tannock I. F. · Cancer Res. · 1989 · 49 · 4373
29. 10.1038/s41568-018-0006-710.1038/s41568-018-0006-7 ↗